2021
Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation
Sewanan LR, Park J, Rynkiewicz MJ, Racca AW, Papoutsidakis N, Schwan J, Jacoby DL, Moore JR, Lehman W, Qyang Y, Campbell SG. Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. The Journal Of General Physiology 2021, 153: e202012640. PMID: 34319370, PMCID: PMC8321830, DOI: 10.1085/jgp.202012640.Peer-Reviewed Original ResearchConceptsHypertrophic cardiomyopathyHeart tissueCellular hypertrophyEngineered Heart TissuePathological cardiac hypertrophyThin filament mutationsMavacamten treatmentDiastolic dysfunctionDisease featuresHypertrophic effectCardiac hypertrophyContractile differencesHypertrophyFundamental disease mechanismsCrossbridge activityInherited disorderOverall Ca2Uncertain significancePatient phenotypesDisease mechanismsLow Ca2PatientsK mutationMavacamtenTissue
2019
Use of Human Cells and Heart Muscle Tissue Patches as Therapeutics for Heart Diseases
Batty L, Ellis M, Anderson C, Luo J, Riaz M, Park J, Das S, Huang Y, Jacoby D, Campbell S, Qyang Y. Use of Human Cells and Heart Muscle Tissue Patches as Therapeutics for Heart Diseases. 2019 DOI: 10.1016/b978-0-12-801238-3.65542-3.ChaptersCardiac tissue engineeringThree-dimensional tissuesCardiovascular disease epidemicRegenerative medicineTissue engineeringCardiac patchesCardiovascular healthHeart diseaseInfarcted tissueClinical useHydrogel matrixStem cellsCardiomyocytesTissue patchesRecent innovationsDisease epidemicsTissueFurther researchHuman cells